2.Alemtuzumab, a humanized anti-CD52 antibody, has shown promise in tolerogenic induction protocols, requiring minimal maintenance immunosuppression.
阿仑单,一种人源性-CD52,在免疫耐受诱导方案中效果显著,需要最少的免疫抑制维持物.
3.Therapeutic mAbs has developed from reshaping antibody and humanized antibody to fully human antibody in order to lower supersensitivity resulting from mouse antibody.